Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Recruiting
Observational Study
Colorectal Cancer (CRC)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,200 (estimated)
- Sponsor
- Epiliquid Holding, Inc · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Men and women aged 45-75 years
* Indication of colorectal cancer screening colonoscopy by treating physician
Exclusion Criteria:
* First-degree family history of CRC
* Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
* Other malignancies within 5 years
* Know…
Contacts